Resmed Inc. RMD

NYS: RMD | ISIN: US7611521078   2/01/2026
244,81 USD (+1,64%)
(+1,64%)   2/01/2026

3 september 2025 · Resmed Launches Sleep Institute to Elevate Sleep Health as a Global Priority · Persbericht

27 augustus 2025 · Obstructive Sleep Apnea Expected to Affect Nearly 77 million U.S. Adults by 2050, New Resmed Study Finds · Persbericht

21 augustus 2025 · Resmed Strengthens Innovation Leadership with Dual Red Dot Design Awards and 10,000 Patents and Designs · Persbericht

18 augustus 2025 · Resmed Announces Election of Nicole Mowad-Nassar to Board of Directors and Upcoming Retirement of Rich Sulpizio · Persbericht

15 mei 2025 · Resmed Champions Sleep Health as The Official Sleep Partner of The Qatar Airways British & Irish Lions Tour to Australia 2025 · Persbericht

1 mei 2025 · Resmed Acquires VirtuOx · Persbericht

21 april 2025 · Resmed Names Salli Schwartz as Chief Investor Relations Officer · Persbericht

19 maart 2025 · New Global Study Finds: Sleep Apnea Patients Who Use CPAP Live Longer · Persbericht

11 maart 2025 · Resmed Unveils Unified Brand to Lead the Global Sleep and Health Technology Revolution · Persbericht

26 februari 2025 · ResMed’s Fifth Annual Global Sleep Survey Reveals a World Struggling with Poor Sleep · Persbericht

10 september 2024 · Vaping Expected to Increase COPD Health and Economic Burden by 2050 · Persbericht

10 juni 2024 · PAP Therapy Reduces Hospitalizations by 31% and ER Visits by 23% for People with Obstructive Sleep Apnea and Comorbid Insomnia · Persbericht

15 maart 2024 · ResMed's 2024 Global Sleep Survey Uncovers a World in Sleep Crisis · Persbericht

9 november 2023 · ResMed Adopts New Operating Model to Accelerate Long-term Growth · Persbericht

6 oktober 2023 · Thinking about trading options or stock in Apple, Super Micro Computer, Pioneer Natural Resources, Shoals Technologies Group, or Resmed? · Persbericht

5 juli 2023 · ResMed Acquires Somnoware, a Leader in Digital Sleep and Respiratory Care Diagnostics Software · Persbericht

8 juni 2023 · PAP Adherence Lowers ER Visits 24-36% in 1 Year for People with Sleep Apnea and Heart Failure: ResMed Studies Presented at SLEEP · Persbericht

25 mei 2023 · 3 World-Renowned Sleep Apnea Experts Present New Benefits of PAP Therapies at ATS 2023 · Persbericht

2 mei 2023 · ResMed Appoints Michael Rider its Next Global General Counsel, Dawn Haake its First Chief Quality Officer · Persbericht

30 maart 2023 · ResMed Chief Administrative Officer and Global General Counsel to Retire · Persbericht

Mijn selecties